Literature DB >> 28484934

Novel antimitotic agents related to tubuloclustin: synthesis and biological evaluation.

Olga N Zefirova1,2, Evgeniya V Nurieva3, Birgit Wobith4, Vladimir V Gogol1, Nikolay A Zefirov1, Andrei V Ogonkov4, Dmitrii V Shishov1, Nikolay S Zefirov1, Sergei A Kuznetsov4.   

Abstract

Tubuloclustin [N-(7-adamant-2-yloxy-7-oxoheptanoyl)-N-deacetylcolchicine], a highly cytotoxic anti-tubulin compound is known for its ability to promote microtubule disassembly followed by the formation of tubulin clusters of unique morphology. Three series of antimitotic agents related to tubuloclustin were designed and synthesized in order to enhance the molecular diversity of "tubuloclustin-like" family of compounds. The series of compounds with modified adamantane moiety was highly potent in cytotoxic effect on human lung carcinoma A549 cells (EC50 = 6-400 nM) and was active in affecting the microtubule arrays and induction of strong tubulin clusterization. In two other sets of compounds, the colchicine moiety of tubuloclustin was replaced by podophyllotoxin or combretastatin A-4. All combretastatin A-4 derivatives displayed noticeable cytotoxic activity ([Formula: see text]) but their effect on microtubules depended on the position of the linker attachment. Podophyllotoxin derivatives were also toxic to A549 cells ([Formula: see text]) and caused both microtubule depolymerization and some tubulin clustering. The data obtained gave additional evidence that the whole panel of C7-colchicine, podophyllotoxin and combretastatin derivatives could manifest clustering effect, and the strength of this effect correlated with cytotoxic activity of the compounds.

Entities:  

Keywords:  Adamantane; Colchicine; Combretastatin; Cytotoxicity; Podophyllotoxin; Tubuloclustin

Mesh:

Substances:

Year:  2017        PMID: 28484934     DOI: 10.1007/s11030-017-9739-6

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  11 in total

1.  Novel syntheses of cis and trans isomers of combretastatin A-4.

Authors:  K Gaukroger; J A Hadfield; L A Hepworth; N J Lawrence; A T McGown
Journal:  J Org Chem       Date:  2001-11-30       Impact factor: 4.354

2.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

3.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.

Authors:  Tam Luong Nguyen; Connor McGrath; Ann R Hermone; James C Burnett; Daniel W Zaharevitz; Billy W Day; Peter Wipf; Ernest Hamel; Rick Gussio
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

4.  Unusual tubulin-clustering ability of specifically c7-modified colchicine analogues.

Authors:  Olga N Zefirova; Heiko Lemcke; Margareta Lantow; Evgeniya V Nurieva; Birgit Wobith; Galina E Onishchenko; Antje Hoenen; Gareth Griffiths; Nikolay S Zefirov; Sergei A Kuznetsov
Journal:  Chembiochem       Date:  2013-07-10       Impact factor: 3.164

5.  Myosin Va bound to phagosomes binds to F-actin and delays microtubule-dependent motility.

Authors:  A Al-Haddad; M A Shonn; B Redlich; A Blocker; J K Burkhardt; H Yu; J A Hammer; D G Weiss; W Steffen; G Griffiths; S A Kuznetsov
Journal:  Mol Biol Cell       Date:  2001-09       Impact factor: 4.138

6.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

7.  New antitubulin derivatives in the combretastatin A4 series: synthesis and biological evaluation.

Authors:  Christine Borrel; Sylviane Thoret; Xavier Cachet; Daniel Guénard; François Tillequin; Michel Koch; Sylvie Michel
Journal:  Bioorg Med Chem       Date:  2005-06-01       Impact factor: 3.641

8.  Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin.

Authors:  Joshua D Bagnato; Alanna L Eilers; Robert A Horton; Charles B Grissom
Journal:  J Org Chem       Date:  2004-12-24       Impact factor: 4.354

Review 9.  Drugs that target dynamic microtubules: a new molecular perspective.

Authors:  Richard A Stanton; Kim M Gernert; James H Nettles; Ritu Aneja
Journal:  Med Res Rev       Date:  2011-03-04       Impact factor: 12.944

10.  Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.

Authors:  Antonios Kolocouris; Christina Tzitzoglaki; F Brent Johnson; Roland Zell; Anna K Wright; Timothy A Cross; Ian Tietjen; David Fedida; David D Busath
Journal:  J Med Chem       Date:  2014-05-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.